Gilead Sciences, Inc.
- GILD
- NASDAQ
- Drug manufacturers
- Biopharmaceuticals (Antivirals)
- HIV Treatment
$154.63
Today −1.00%Quote Oct 19, 2026, 04:10 PM UTC
+3.51%over the last month
Max drawdown −5.5%From 1-month high −0.7%3 months +17.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Gilead Sciences
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs.
Where the money comes from
Q2 2026 revenue $7.80B
- Total HIV$5.69B73.0%
- Total Liver Disease$877.0M11.2%
- Total Oncology$873.0M11.2%
- Royalty, contract and other revenues$176.0M2.3%
- Total Other$161.0M2.1%
Sector
Healthcare
Industry
Drug manufacturers
Exchange
NASDAQ
Employees
17,000
Founded
1987
Market value
$191.73B
Quote Oct 19
Floor
$154.21
0.3% below price
Resistance
$156.50
1.2% above price
Price vs analyst targets
58 analysts
Lowest target
$126.00Highest target
$175.00
$126.00Highest target
$175.00
- Price $154.63
- Average target $153.13
- Analysts' target range
Analysts' average target sits about 1% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GILDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free